World Health Organization. WHO endorses new rapid tuberculosis test. 2010. Available from: http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/. Accessed on 15/12/2014.
World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system.; 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241501545_eng.pdf. Accessed on 31–01-2012.
World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335_eng.pdf. Accessed on 15/12/2014.
Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016;48(2):516–25.
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347.
Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012;7(5):e36966.
Dowdy DW, Davis JL, den Boon S, Walter ND, Katamba A, Cattamanchi A. Population-level impact of same-day microscopy and Xpert MTB/RIF for tuberculosis diagnosis in Africa. PLoS One. 2013;8(8):e70485.
Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383(9915):424–35.
Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med. 2014;11(11):e1001760.
Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med. 2014;11(12):e1001766.
Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health. 2015;3(8):e450–7. doi:10.1016/S2214-109X(15)00100-X.
Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis. 2014;14(6):527–32.
Schumacher SG, Sohn H, Qin ZZ, Gore G, Davis JL, Denkinger CM, et al. Impact of molecular diagnostics for tuberculosis on patient-important outcomes: a systematic review of study methodologies. PLoS One. 2016;11(3):e0151073.
Hermans SM, Castelnuovo B, Katabira C, Mbidde P, Lange JM, Hoepelman AI, et al. Integration of HIV and TB services results in improved TB treatment outcomes and earlier, prioritized ART initiation in a large urban HIV clinic in Uganda. J Acquir Immune Defic Syndr. 2012;60(2):e29–35.
Hermans SM, Nasuuna E, Van Leth F, Byhoff E, Schwarz M, Hoepelman A, et al. Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study. BMC Public Health. 2012;12:674.
Nakiyingi L, Bwanika JM, Kirenga B, Nakanjako D, Katabira C, Lubega G, et al. Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS One. 2013;8(9):e74023.
Bakari M, Arbeit RD, Mtei L, Lyimo J, Waddell R, Matee M, et al. Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis. 2008;8:32.
Katagira W, Walter ND, Den Boon S, Kalema N, Ayakaka I, Vittinghoff E, et al. Empiric TB treatment of severely ill patients with HIV and presumed pulmonary TB improves survival. J Acquir Immune Defic Syndr. 2016;72(3):297–303.
Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;1:CD009593. doi:10.1002/14651858.CD009593.pub3.
Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495–505.
McCarthy KM, Grant AD, Chihota V, Ginindza S, Mvusi L, Churchyard GJ, et al. Implementation and operational research: what happens after a negative test for tuberculosis? Evaluating adherence to TB diagnostic algorithms in South African primary health clinics. J Acquir Immune Defic Syndr. 2016;71(5):e119–26.
Manabe YC, Zawedde-Muyanja S, Burnett SM, Mugabe F, Naikoba S, Coutinho A. Rapid improvement in passive tuberculosis case detection and tuberculosis treatment outcomes after implementation of a bundled laboratory diagnostic and on-site training intervention targeting mid-level providers. Open Forum Infect Dis. 2015;2(1):ofv030. doi:10.1093/ofid/ofv030.
Schumacher SG, Nabeta P, Boehme C, Ellner J, Alland D, Dorman SE, et al. A multicenter diagnostic accuracy study of the Xpert Ultra for tuberculosis diagnosis. Conference for Retrovirology and Opportunistic Infections; 13–16 February 2017; Seattle, USA, 2017. Abstract 76LB.
Hanrahan CF, Haguma P, Ochom E, Kinera I, Cobelens F, Cattamanchi A, et al. Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis. Open Forum Infect Dis. 2016;3(2):ofw068. doi:10.1093/ofid/ofw068.
Mbonze NB, Tabala M, Wenzi LK, Bakoko B, Brouwer M, Creswell J, et al. Xpert((R)) MTB/RIF for smear-negative presumptive TB: impact on case notification in DR Congo. Int J Tuberc Lung Dis. 2016;20(2):240–6.
Sikhondze W, Dlamini T, Khumalo D, Maphalala G, Dlamini S, Zikalala T, et al. Countrywide roll-out of Xpert((R)) MTB/RIF in Swaziland: the first three years of implementation. Public Health Action. 2015;5(2):140–6.
Hermans S, Caldwell J, Kaplan R, Cobelens F, Wood R. The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa. Bull World Health Organ. 2017; E-pub date 28–04-2017. Available from: http://www.who.int/bulletin/online_first/BLT.16.185314.pdf?ua=1
Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet.387(10024):1198–209.
Manabe YC, Worodria W, van Leth F, Mayanja-Kizza H, Traore AN, Ferro J, et al. Prevention of early mortality by presumptive tuberculosis therapy study: an open label. American Journal of Tropical Medicine and Hygiene: Randomized Controlled Trial; 2016.
Grant A, Charalambous S, Tlali M, Johnson S, Dorman SE, Hoffman C, et al. Empirical TB Treatment in Advanced HIV Disease: Results of the TB Fast Track Trial. Conference on Retroviruses and Opportunistic Infections; 22–25 February 2016; Boston, Massachusetts, USA, 2016.